The FDA has cleared the Elecsys pTau181 test as an aid in early detection of amyloid pathology in the primary care setting for adults aged 55 years and older presenting with signs, symptoms or ...

Open-access publication demonstrates the validity and reliability of the Mentavi online Diagnostic Evaluation compared to a clinical interview, widening evidence based telehealth access for adults ...

Acorai, a clinical-stage company pioneering non-invasive hemodynamic monitoring for heart failure management, this week ...

Grail announced fresh data on Friday from a large U.S. study of its flagship Galleri blood-based test for detecting dozens of ...

A second blood test has been been approved by the US Food and Drug Administration to assist in diagnosing Alzheimer’s disease ...

The centerpiece of Ultra V3 is the Iris router, which replaces Jupiter’s retired Metis system. According to Jupiter Exchange, ...

The FDA has granted 510(k) clearance to a blood-based biomarker test indicated for early detection of Alzheimer’s disease and other causes of cognitive decline within a primary care setting, according ...

The test is intended for adults 55 and older in the United States who are showing signs or symptoms of cognitive decline.

Eli Lilly and Company (NYSE: LLY) today announced that new data from across its oncology portfolio and pipeline will be ...

Humans touch their faces up to 800 times each day, and most of it happens completely outside conscious awareness.